Compare TNXP & NCRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | NCRA |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.7M | 5.6M |
| IPO Year | 2008 | 2022 |
| Metric | TNXP | NCRA |
|---|---|---|
| Price | $12.98 | $0.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 407.6K | ★ 442.1K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,107,000.00 | N/A |
| Revenue This Year | $558.11 | N/A |
| Revenue Next Year | $38.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 29.85 | N/A |
| 52 Week Low | $11.60 | $0.18 |
| 52 Week High | $69.65 | $2.40 |
| Indicator | TNXP | NCRA |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 34.93 |
| Support Level | $11.60 | $0.18 |
| Resistance Level | $20.36 | $0.32 |
| Average True Range (ATR) | 1.13 | 0.03 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 24.96 | 24.44 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.